Protocol Ledger

NCT04587830 · Phase II · ACTIVE NOT RECRUITING

ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme

Interventional Phase II clinical trial protocol NCT04587830 sponsored by Polaris Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-14 Enrollment: 100 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04587830
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04587830
Protocol FieldVerified Registry Value
NCT IdentifierNCT04587830
Consolidated Lead SponsorPolaris Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment100 participants (ACTUAL)
Registered Start Date2020-09-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04587830
Hospital Research SiteLocationSite Profile
Seoul National University HospitalSeoul, South KoreaOpen Hospital Dossier ->
National Taiwan University HospitalTaipei, TaiwanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI